154 related articles for article (PubMed ID: 30573649)
1. Double trouble? Gag in conjunction with double insert in HIV protease contributes to reduced DRV susceptibility.
Williams A; Basson A; Achilonu I; Dirr HW; Morris L; Sayed Y
Biochem J; 2019 Jan; 476(2):375-384. PubMed ID: 30573649
[TBL] [Abstract][Full Text] [Related]
2. An insight to the molecular interactions of the FDA approved HIV PR drugs against L38L↑N↑L PR mutant.
Sanusi ZK; Govender T; Maguire GEM; Maseko SB; Lin J; Kruger HG; Honarparvar B
J Comput Aided Mol Des; 2018 Mar; 32(3):459-471. PubMed ID: 29397520
[TBL] [Abstract][Full Text] [Related]
3. Drug susceptibility and replication capacity of a rare HIV-1 subtype C protease hinge region variant.
Zondagh J; Basson AE; Achilonu I; Morris L; Dirr HW; Sayed Y
Antivir Ther; 2019; 24(5):333-342. PubMed ID: 30958309
[TBL] [Abstract][Full Text] [Related]
4. Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1.
Sutherland KA; Mbisa JL; Cane PA; Pillay D; Parry CM
J Gen Virol; 2014 Jan; 95(Pt 1):190-200. PubMed ID: 24172906
[TBL] [Abstract][Full Text] [Related]
5. Molecular dynamics and ligand docking of a hinge region variant of South African HIV-1 subtype C protease.
Zondagh J; Balakrishnan V; Achilonu I; Dirr HW; Sayed Y
J Mol Graph Model; 2018 Jun; 82():1-11. PubMed ID: 29625416
[TBL] [Abstract][Full Text] [Related]
6. Purification and characterization of naturally occurring HIV-1 (South African subtype C) protease mutants from inclusion bodies.
Maseko SB; Natarajan S; Sharma V; Bhattacharyya N; Govender T; Sayed Y; Maguire GE; Lin J; Kruger HG
Protein Expr Purif; 2016 Jun; 122():90-6. PubMed ID: 26917227
[TBL] [Abstract][Full Text] [Related]
7. Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.
Larrouy L; Vivot A; Charpentier C; Bénard A; Visseaux B; Damond F; Matheron S; Chene G; Brun-Vezinet F; Descamps D;
AIDS; 2013 Jan; 27(1):69-80. PubMed ID: 23018441
[TBL] [Abstract][Full Text] [Related]
8. HIV Protease Hinge Region Insertions at Codon 38 Affect Enzyme Kinetics, Conformational Stability and Dynamics.
Sheik Ismail Z; Worth R; Mosebi S; Sayed Y
Protein J; 2023 Oct; 42(5):490-501. PubMed ID: 37421557
[TBL] [Abstract][Full Text] [Related]
9. Modeling the full length HIV-1 Gag polyprotein reveals the role of its p6 subunit in viral maturation and the effect of non-cleavage site mutations in protease drug resistance.
Su CT; Kwoh CK; Verma CS; Gan SK
J Biomol Struct Dyn; 2018 Dec; 36(16):4366-4377. PubMed ID: 29237328
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.
Blanch-Lombarte O; Santos JR; Peña R; Jiménez-Moyano E; Clotet B; Paredes R; Prado JG
J Antimicrob Chemother; 2020 Sep; 75(9):2535-2546. PubMed ID: 32556165
[TBL] [Abstract][Full Text] [Related]
11.
Datir R; Kemp S; El Bouzidi K; Mlchocova P; Goldstein R; Breuer J; Towers GJ; Jolly C; Quiñones-Mateu ME; Dakum PS; Ndembi N; Gupta RK
mBio; 2020 Nov; 11(6):. PubMed ID: 33144375
[TBL] [Abstract][Full Text] [Related]
12. Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.
Giandhari J; Basson AE; Sutherland K; Parry CM; Cane PA; Coovadia A; Kuhn L; Hunt G; Morris L
Antimicrob Agents Chemother; 2016 Apr; 60(4):2248-56. PubMed ID: 26833162
[TBL] [Abstract][Full Text] [Related]
13. Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.
Martins AN; Waheed AA; Ablan SD; Huang W; Newton A; Petropoulos CJ; Brindeiro RD; Freed EO
J Virol; 2016 Jan; 90(2):768-79. PubMed ID: 26512081
[TBL] [Abstract][Full Text] [Related]
14. Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch.
Eche S; Kumar A; Sonela N; Gordon ML
Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33805099
[TBL] [Abstract][Full Text] [Related]
15. An in silico pharmacological approach toward the discovery of potent inhibitors to combat drug resistance HIV-1 protease variants.
Nayak C; Chandra I; Singh SK
J Cell Biochem; 2019 Jun; 120(6):9063-9081. PubMed ID: 30506751
[TBL] [Abstract][Full Text] [Related]
16. Wide variation in susceptibility of transmitted/founder HIV-1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency.
Sutherland KA; Collier DA; Claiborne DT; Prince JL; Deymier MJ; Goldstein RA; Hunter E; Gupta RK
Sci Rep; 2016 Nov; 6():38153. PubMed ID: 27901085
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length Gag-protease genes.
Sutherland KA; Mbisa JL; Ghosn J; Chaix ML; Cohen-Codar I; Hue S; Delfraissy JF; Delaugerre C; Gupta RK
J Antimicrob Chemother; 2014 Dec; 69(12):3340-8. PubMed ID: 25096075
[TBL] [Abstract][Full Text] [Related]
18. GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.
Delino NS; Aoki M; Hayashi H; Hattori SI; Chang SB; Takamatsu Y; Martyr CD; Das D; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463535
[TBL] [Abstract][Full Text] [Related]
19. Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals.
Sakai K; Chikata T; Brumme ZL; Brumme CJ; Gatanaga H; Oka S; Takiguchi M
Retrovirology; 2015 Nov; 12():98. PubMed ID: 26585907
[TBL] [Abstract][Full Text] [Related]
20. Transient HIV-1 Gag-protease interactions revealed by paramagnetic NMR suggest origins of compensatory drug resistance mutations.
Deshmukh L; Louis JM; Ghirlando R; Clore GM
Proc Natl Acad Sci U S A; 2016 Nov; 113(44):12456-12461. PubMed ID: 27791180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
